LOS ANGELES, Sept. 9, 2022 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of what’s to come October 17, 2022 Deadline for filing a motion by lead plaintiff in the class action lawsuit filed on behalf of investors who have purchased or otherwise acquired Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) AMPE common stock in between December 29, 2020 and August 3, 2022inclusive (the “Class Period”).

If you have suffered a loss on your Ampio investments or would like to inquire about the possibility of making claims to recover your loss under the federal securities laws, you may submit your contact information at www.glancylaw.com/cases/ampio-pharmaceuticals-inc-1/. You can also contact GPM’s Charles H. Linehan at 310-201-9150, toll free at 888-773-9224, or email at [email protected] to learn more about your rights.

On April 20, 2022, Ampio announced that the U.S. Food and Drug Administration (“FDA”) had responded negatively to its Type-C meeting request for the Company’s AP-013 clinical study and that the FDA believed that the company should have obtained FDA approval for changes to data analysis prior to analyzing and unblinding the data. As a result of this news, the company’s share price fell $0.09, or 26%, to close at $0.25 per share on April 21, 2022.

Then, on May 16, 2022, Ampio announced that it had formed a special committee to conduct an internal investigation focused on Ampio’s AP-013 clinical trial and the unauthorized making available of its anti-inflammatory drug, Ampion, for use by people who are not participate in clinical trials. As a result of this news, the company’s share price fell $0.04, or 10%, to close at $0.18 per share on May 18, 2022.

Then, on August 3, 2022, Ampio announced that as early as March 2020, “senior personnel were aware … that the AP-013 study did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function; and that these individuals will receive the results of the AP-013 study and the timing of the unblinding of the data from…